DEA Scheduling as a Pain Severity Indicator: A Clinical Pearl for PI Attorneys

Amar Lunagaria — Co-Founder & Chief Pharmacist, LienScripts | March 4, 2026 | 9 min read

The DEA schedule of a prescribed controlled substance objectively classifies the medication's potency and abuse potential. Learn how to use DEA scheduling in pharmacy records to establish a graduated severity framework that proves the plaintiff's pain required increasingly potent pharmacological intervention.

The DEA Controlled Substance Schedule is a federally mandated classification system that ranks medications from Schedule I (highest abuse potential, no accepted medical use) through Schedule V (lowest abuse potential among controlled substances). When a plaintiff's pharmacy records show progression from non-controlled medications to Schedule IV, Schedule III, or Schedule II substances, that progression documents a federally recognized escalation in the potency of treatment required to manage their injury -- an objective severity indicator that carries the weight of federal regulatory authority.

• DEA scheduling provides a federally standardized severity framework -- higher schedule numbers mean the federal government recognizes greater potency and abuse potential, and prescribers face greater regulatory scrutiny for prescribing them
• Progression up the schedule (from non-controlled to Schedule V to Schedule IV to Schedule III to Schedule II) documents that each prior treatment level was insufficient
• Schedule II prescriptions require separate prescriptions for each fill with no refills, imposing regulatory burden that prescribers accept only for significant clinical need
• LienScripts tracks the DEA schedule of every dispensed medication and includes scheduling analysis in every MERIT (Medication Evaluation & Rationale for Injury Treatment) report
• The federal regulatory framework surrounding controlled substances is itself evidence of severity -- prescribers do not casually prescribe Schedule II medications

Understanding the DEA Schedule

Schedule V -- Lowest Controlled Classification

Schedule V medications have the lowest abuse potential among controlled substances. Examples in PI cases include:

• Pregabalin (Lyrica) -- neuropathic pain agent, reclassified to Schedule V
• Certain cough preparations with limited codeine concentrations
• Lacosamide -- sometimes used for neuropathic pain

A prescription for a Schedule V medication indicates pain or symptoms significant enough to warrant a controlled substance, but at the lowest tier of regulatory concern.

Schedule IV -- Moderate-Low Abuse Potential

Schedule IV medications carry moderate-low abuse potential and include several drugs commonly prescribed in PI cases:

• Tramadol -- lower-potency opioid analgesic
• Benzodiazepines (diazepam, lorazepam, alprazolam) -- for acute anxiety, muscle spasm, or sleep disruption
• Zolpidem (Ambien) -- for accident-related insomnia
• Carisoprodol (Soma) -- muscle relaxant

Prescribing a Schedule IV medication indicates the prescriber determined that non-controlled alternatives (gabapentin, cyclobenzaprine, hydroxyzine) were insufficient.

Schedule III -- Moderate Abuse Potential

Schedule III includes medications with moderate abuse potential:

• Buprenorphine-containing products -- for pain management or opioid transition
• Testosterone (in rare PI contexts -- post-traumatic hormonal dysfunction)
• Ketamine formulations -- increasingly used for refractory pain
• Certain combination products with limited opioid quantities

Schedule III prescribing documents a step above Schedule IV in the severity-treatment continuum.

Schedule II -- Highest Prescribed Abuse Potential

Schedule II represents the highest abuse potential among medications with accepted medical use. These are the most tightly regulated prescribed medications in the United States:

• Oxycodone (OxyContin, Percocet, Roxicodone)
• Hydrocodone combination products (Vicodin, Norco)
• Morphine
• Fentanyl (patches, lozenges)
• Methadone (for pain)
• Amphetamine salts (in cases involving post-TBI cognitive impairment)
• Methylphenidate (post-concussion attention deficits)

Schedule II prescriptions carry the most restrictive regulatory requirements. They cannot be refilled -- each fill requires a new prescription from the prescriber. In many states, the prescriber must use a special prescription pad or electronic prescribing system. This regulatory burden exists because the federal government has determined these medications carry the highest risk among prescribed drugs.

As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist explains, "A Schedule II prescription is not written casually. The prescriber knows they are documenting their name on a DEA-tracked prescription for a medication the federal government considers high-risk. They accept that regulatory scrutiny because the patient's clinical condition demands this level of pharmacological intervention. That is powerful severity evidence."

The Severity Escalation Framework

The most compelling use of DEA scheduling in litigation is to present the plaintiff's medication trajectory as a federally recognized escalation in treatment intensity:

Level 1: Non-Controlled Medications

• Over-the-counter analgesics (acetaminophen, ibuprofen)
• Prescription NSAIDs (meloxicam, celecoxib)
• Non-controlled muscle relaxants (cyclobenzaprine, methocarbamol)
• Non-controlled neuropathic agents (gabapentin, amitriptyline)

Level 2: Schedule V Controlled Substances

• Pregabalin for neuropathic pain

Level 3: Schedule IV Controlled Substances

• Tramadol for moderate pain
• Benzodiazepines for accident-related anxiety or spasm

Level 4: Schedule III Controlled Substances

• Buprenorphine products
• Certain combination analgesics

Level 5: Schedule II Controlled Substances

• Oxycodone, hydrocodone, morphine, fentanyl for severe pain
• Stimulants for post-TBI cognitive impairment

A plaintiff whose pharmacy record shows progression from Level 1 through Level 5 over a treatment period has objective, federally-framework-supported evidence that their pain required increasingly potent intervention. Each step up was a prescriber's clinical decision documented in a system monitored by the DEA.

Presenting DEA Schedule Evidence

In Demand Packages

In every demand package involving controlled substances, frame the medications within the DEA scheduling hierarchy:

"The plaintiff's treatment began with non-controlled medications including meloxicam and gabapentin. When these proved insufficient, the prescriber escalated to tramadol (DEA Schedule IV). When tramadol failed to adequately manage the plaintiff's pain, the prescriber progressed to oxycodone (DEA Schedule II) -- the most tightly regulated category of prescribed medication under federal law. This progression through three levels of the federal controlled substance framework documents that the plaintiff's pain required the most potent category of analgesic available."

In MERIT Reports

LienScripts includes DEA scheduling context in every MERIT report, identifying each controlled substance by schedule and explaining the regulatory significance of the prescribing decision.

Regulatory Burden as Severity Evidence

The regulatory requirements surrounding Schedule II medications are themselves evidence of severity:

• No refills permitted -- the prescriber must write a new prescription for every fill, requiring ongoing clinical evaluation
• DEA registration required -- the prescriber's DEA number appears on every controlled substance prescription, creating a personal accountability record
• Prescription Drug Monitoring Program (PDMP) reporting -- every controlled substance fill is reported to the state PDMP database, creating a government-maintained record
• Quantity limitations -- many states and insurers limit the quantity of Schedule II medications per fill

A prescriber who navigates all of these regulatory requirements to provide a plaintiff with a Schedule II medication has made a significant clinical commitment that documents the severity of the plaintiff's condition.

Countering Defense Arguments

"The plaintiff is simply drug-seeking."

The DEA's regulatory framework and PDMP monitoring are specifically designed to prevent inappropriate prescribing. A plaintiff who receives controlled substance prescriptions through a single prescriber, fills at a consistent pharmacy, and has PDMP records showing appropriate use is not drug-seeking -- they are receiving clinically appropriate treatment under federal oversight.

"Opioids are over-prescribed for minor injuries."

Whether opioids are over-prescribed generally is irrelevant to this specific plaintiff's case. The prescriber evaluated this patient's specific clinical condition and determined that a Schedule II medication was warranted. The prescriber's individualized clinical judgment is the relevant evidence.

"The plaintiff should have used non-opioid alternatives."

The treatment trajectory documented in pharmacy records typically shows that the plaintiff did use non-opioid alternatives first, and they were insufficient. The progression to controlled substances was not the starting point -- it was the escalation point after lower levels of treatment failed.

The Clinical Pearl

The DEA Controlled Substance Schedule is a federally established framework for classifying medication potency and risk. When a plaintiff's pharmacy records show progression through this framework -- from non-controlled medications to Schedule IV to Schedule II -- the treatment trajectory carries the authority of federal regulatory classification. This is not the plaintiff's characterization of their pain. It is the federal government's classification of the medications their condition required, documented through prescriber decisions tracked by the DEA.

LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report for every case, providing pharmacist-signed documentation for demand packages that includes DEA scheduling analysis for every controlled substance in the plaintiff's regimen.

Related Resources

• Black Box Warning Medications as Severity Evidence -- How FDA safety warnings prove clinical severity
• Dose Escalation Documents Injury Progression -- Using dose increases to prove worsening symptoms